⚡ Quick Start — If You Read Nothing Else

The 10 most important things to know right now.

“Head and neck cancer” is really many different cancers. Where the cancer starts — mouth, throat (oropharynx), voice box (larynx), lower throat (hypopharynx), upper throat behind the nose (nasopharynx), salivary glands, or sinuses — changes the treatment and the outlook. Ask exactly which subsite you have.
If it's in the throat/tonsil/base of tongue, ask whether it is HPV-positive. Many oropharyngeal cancers are caused by the human papillomavirus (HPV). HPV-positive throat cancer responds much better to treatment and has higher cure rates. Your tumor should be tested for a marker called p16/HPV, because it changes your stage and your outlook.
Most head and neck cancer is curable — especially when found early. Early-stage disease is often cured with a single treatment (surgery alone or radiation alone). More advanced disease is frequently cured too, using combinations — often while preserving your voice and your ability to swallow.
See a dentist BEFORE radiation. Radiation to the head and neck can cause a serious jaw bone complication (osteoradionecrosis). A dental check-up — with any needed extractions done before radiation starts — is one of the most important steps to prevent it. Do not skip it.
You need a team, not one doctor. The best outcomes come from a multidisciplinary team: head and neck surgeon, radiation oncologist, medical oncologist, plus dentistry, speech-language pathology, and nutrition. Ask whether your case will be reviewed at a tumor board.
Chemotherapy is often given with radiation, not instead of it. For locally advanced disease, the chemotherapy cisplatin given alongside radiation raises cure rates. A different drug, cetuximab, is used mainly when cisplatin can't be given — it is a fallback, not an equal substitute.
Immunotherapy has changed advanced disease — and is now moving earlier. Drugs that release the brakes on the immune system (pembrolizumab, nivolumab) help many people with cancer that has come back or spread live longer. As of June 2025, pembrolizumab around surgery is FDA-approved for resectable locally advanced disease (the KEYNOTE-689 trial) — bringing immunotherapy into potentially curable disease.
Nasopharyngeal cancer is its own disease. Cancer of the nasopharynx (upper throat behind the nose) is usually linked to the Epstein-Barr virus (EBV), is treated with chemotherapy and radiation (and now immunotherapy such as toripalimab), and can be monitored with a blood test for EBV DNA.
“Gentler” treatment for HPV-positive cancer is still experimental. Researchers are testing lower-dose radiation and less chemotherapy to reduce long-term side effects. A major recent US trial (NRG-HN005) found the standard treatment still worked better. So de-escalation should only be done inside a clinical trial for now.
Watch for emergencies and persistent symptoms. A sore in the mouth or throat that won't heal, a neck lump, ongoing hoarseness, painful or difficult swallowing, one-sided ear pain, or nasal blockage/bleeding lasting more than 2–3 weeks deserves prompt evaluation by an ENT. During treatment, trouble breathing, heavy bleeding from the mouth/throat, or inability to swallow your own saliva are emergencies.

▼ Collapse

Understanding Head and Neck Cancer

A diagnosis of head and neck cancer is frightening, and the words can be confusing — “squamous cell carcinoma,” “oropharynx,” “p16,” “CPS.” This guide is here to translate. Our goal is to help you understand what kind of cancer you have, what your choices are, and what questions to ask so you can get the best possible care.

Here is the single most important idea: head and neck cancer is not one disease. It is a family of cancers that start in different places — and the place where it starts, together with whether it is caused by a virus, changes everything about treatment and outlook. Two people can both have “throat cancer” and face completely different situations.

There is real, evidence-based reason for hope. Most head and neck cancers are curable, and outcomes keep improving. Many early cancers are cured with one treatment. Even locally advanced disease is frequently cured with combinations of surgery, radiation, and chemotherapy — often while keeping your voice and swallowing. HPV-related throat cancers respond especially well, and immunotherapy has extended survival in advanced disease.

What “head and neck cancer” covers

Most head and neck cancers are squamous cell carcinomas — cancers that begin in the flat, skin-like cells lining the mouth and throat. They are grouped by subsite (where they start):

Oral cavity — lips, front of the tongue, gums, floor of the mouth, inside of the cheeks, hard palate. Strongly linked to tobacco, alcohol, and (in parts of Asia) betel/areca-nut chewing.
Oropharynx — tonsils, base (back) of the tongue, soft palate, and back wall of the throat. This is where HPV-related cancer usually arises.
Larynx (voice box) — treatment here focuses heavily on preserving your voice when possible.
Hypopharynx — the lower throat, behind and around the voice box.
Nasopharynx — the upper throat behind the nose. A distinct cancer, usually linked to the Epstein-Barr virus (EBV), most common in parts of southern China and Southeast Asia.
Salivary glands and sinuses/nasal cavity — less common and biologically different; treated somewhat differently (salivary gland cancers are often not squamous cell and follow their own rules).

Over the past 25 years, the causes of throat cancer have shifted in many high-income countries. Historically, head and neck cancer was mostly a disease of heavy tobacco and alcohol use. Now a large and rising share of oropharyngeal (tonsil and base-of-tongue) cancers are caused instead by HPV — the same family of viruses linked to cervical cancer.

This matters enormously because HPV-positive oropharyngeal cancer behaves very differently. It tends to occur in somewhat younger, healthier, non-smoking patients, and it is much more curable — cure rates are high even when lymph nodes in the neck are involved. Because of this, doctors use a separate staging system for HPV-positive throat cancer (see the Types & Staging section), and it is the focus of research into gentler treatment. The same HPV vaccine that prevents cervical cancer is expected to prevent many of these throat cancers over time.

How treatment fits together (the big picture)

Treatment depends on your subsite, your stage, and your HPV/EBV status, but the building blocks are:

Surgery — removing the tumor, from minimally invasive transoral robotic surgery (TORS) for selected throat cancers, to larger operations with reconstruction.
Radiation therapy — high-precision X-rays (intensity-modulated radiotherapy, IMRT; sometimes proton therapy) that can cure many head and neck cancers and help preserve organs like the voice box.
Chemotherapy — usually cisplatin given together with radiation (“chemoradiation”) for locally advanced disease.
Immunotherapy — checkpoint inhibitors (pembrolizumab, nivolumab) that unleash the immune system; standard for recurrent/metastatic disease, and now used around surgery in selected locally advanced disease.
Targeted therapy — cetuximab, which blocks the EGFR protein, used in specific situations.
Supportive and rehabilitative care — dental care, nutrition and feeding-tube support, speech and swallowing therapy, pain and dry-mouth management. These are core parts of treatment, not optional extras.

A note on honesty. Outlook genuinely varies: a small, early HPV-positive tonsil cancer in a non-smoker and an advanced hypopharynx cancer in a long-term smoker are very different situations. We will not sugarcoat that. But across the whole spectrum, head and neck cancer is one of the more treatable and often curable cancers, and the tools keep getting better.

Exactly which subsite is my cancer in (oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, salivary, sinus)?
Is my cancer squamous cell carcinoma? If it's in the throat, is it HPV-positive (p16-positive)? If it's in the nasopharynx, was it tested for EBV?
How does my type and HPV/EBV status affect my outlook and my treatment options?
Will my case be reviewed by a multidisciplinary tumor board? Who will be on my team?
What is the overall goal of my treatment — cure, or controlling the cancer?
How do you plan to protect my voice, my swallowing, and my appearance during treatment?

Caregiver note. Head and neck cancer treatment is unusually demanding on caregivers because it affects eating, talking, and breathing — the most basic daily functions. From day one, it helps to set up a simple binder or phone folder for appointments, contacts, and notes, and to plan for someone to come to key appointments. You'll find caregiver tips woven through every section of this guide, plus a dedicated caregiver section under Survivorship.

Getting Diagnosed

The path to diagnosis usually starts with a symptom that won't go away. Because head and neck cancers are often curable when caught early but harder to treat when advanced, persistent symptoms deserve prompt attention.

See an ENT (otolaryngologist) if any of these last more than 2–3 weeks:

A sore in the mouth or throat that doesn't heal, or a white/red patch in the mouth
A lump in the neck (a very common first sign of HPV-related throat cancer)
Persistent hoarseness or a change in your voice (especially >3 weeks — a key warning for larynx cancer)
Pain or difficulty swallowing, or a feeling of something stuck in the throat
Unexplained, persistent one-sided ear pain (referred pain from the throat)
Nasal blockage or bleeding, or hearing loss/fullness in one ear (warning signs for nasopharyngeal cancer)
A loose tooth, ill-fitting denture, or a lump on the gum or jaw with no dental cause

None of these proves cancer — most are something else — but they should be checked, not ignored.

What the workup involves

Getting a clear diagnosis and stage usually takes several steps. This can feel slow, but each step shapes the treatment plan:

Examination. The ENT examines your mouth and throat, often with a thin flexible scope passed through the nose to view the throat and voice box.
Biopsy. A small tissue sample confirms cancer. For a neck lump, this may be a fine-needle aspiration. The tissue is also tested for p16/HPV (for throat cancers) and, when relevant, EBV (for nasopharyngeal cancers).
Imaging. CT and/or MRI map the tumor and lymph nodes; a PET-CT scan checks for spread and for a second cancer. Imaging of the chest is common.
Examination under anesthesia / panendoscopy. A more thorough look at the throat under anesthesia, sometimes done to find a hidden primary tumor or rule out a second cancer.
Baseline dental and nutrition assessment. If radiation is likely, you'll see a dentist (to protect your jaw) and ideally a dietitian and a speech-language pathologist before treatment starts.

For oropharyngeal (throat) cancers, the lab stains the tumor for a protein called p16, which is a reliable marker of HPV-driven cancer, and may run additional HPV tests. A p16-positive result means your cancer is HPV-associated — which generally means a better outlook and places you in a different staging system. This is one of the few times in oncology where a test result is usually good news. (p16/HPV testing is recommended specifically for oropharyngeal cancers; it is not used the same way for other subsites.)

Sometimes the first sign is a cancerous neck lymph node, but doctors can't immediately find where the cancer started. This is called a cancer of unknown primary. Testing the node for HPV/p16 or EBV is a powerful clue: HPV usually points to a hidden oropharynx (tonsil/base-of-tongue) source, and EBV points to the nasopharynx. This guides a targeted search (often including TORS-assisted examination of the tonsils and tongue base) and treatment.

Prepare for your appointments

Bring someone with you. A second set of ears is invaluable when a lot of information comes fast.
Write down your questions in advance and ask permission to record the conversation.
Ask for copies of your pathology report (including p16/HPV or EBV status), staging, and imaging.
Track your weight, what you can eat and drink, pain levels, and any new symptoms in a simple log.

Caregiver note. During the diagnostic phase, your biggest jobs are organization and emotional steadiness. Keep the binder/phone folder updated, help track symptoms and weight, and gently make sure the dental and nutrition appointments actually get booked before treatment — these are easy to overlook in the rush, but they matter for the long term.

What does my biopsy show? Can I have a copy of the pathology report?
Was my tumor tested for p16/HPV (throat) or EBV (nasopharynx)? What was the result and what does it mean?
What scans do I need, and what are they looking for?
Do I need an examination under anesthesia or panendoscopy?
Should I see a dentist, a dietitian, and a speech-language pathologist before treatment starts? Can you refer me now?
How long until we have a full plan, and who is my main point of contact in the meantime?

Types, Subsites & Staging

Staging describes how big the cancer is and whether it has spread. It uses the AJCC 8th-edition system, which combines three things — T (size/extent of the main tumor), N (lymph nodes in the neck), and M (spread to distant organs) — into an overall stage from I (earliest) to IV (most advanced). Your stage strongly shapes treatment.

HPV-positive throat cancer has its own staging. Because HPV-positive oropharyngeal cancer is so much more curable, AJCC-8 created a separate staging system for it. The same neck-node findings that would make an HPV-negative cancer “advanced” may keep an HPV-positive cancer at an earlier stage. So an HPV-positive “stage I” and an HPV-negative “stage I” are not the same thing — don't compare stage numbers across the two.

The subsites at a glance

Cancers of the tongue (front two-thirds), floor of mouth, gums, cheek lining, and hard palate. Most are tobacco/alcohol-related; betel/areca-nut chewing is a major cause in South and Southeast Asia. Surgery is usually the primary treatment, sometimes followed by radiation or chemoradiation depending on what the surgery finds.

Tonsils, base of tongue, soft palate, and throat wall. This is the key fork in the road:

HPV-positive (p16-positive): better prognosis, separate staging, often presents as a neck lump in a non-smoker. Curable at high rates with either radiation-based treatment or surgery (TORS)-based treatment. Focus of de-escalation research.
HPV-negative: usually tobacco/alcohol-related, behaves more like other smoking-related head and neck cancers, and is staged on the standard scale.

Larynx: the central treatment question is often how to cure the cancer while preserving the voice. Early larynx cancers are frequently cured with radiation or with limited surgery, keeping the voice. For more advanced larynx cancer, chemoradiation can often preserve the voice box and avoid removing the larynx (a total laryngectomy) — though surgery remains the right choice for some tumors. Hypopharynx: tends to be diagnosed later and is treated with chemoradiation or surgery plus adjuvant therapy; voice and swallowing preservation are central concerns here too.

Cancer of the upper throat behind the nose. It is usually linked to the Epstein-Barr virus (EBV), is most common in parts of southern China, Southeast Asia, and some North African and Arctic populations, and is treated and monitored differently from other head and neck cancers. Because of its location, surgery is usually not the main treatment — radiation and chemotherapy are, now often with immunotherapy. A blood test for EBV DNA can help estimate risk and watch for recurrence. See the Locally Advanced and Recurrent/Metastatic sections for details.

Salivary gland cancers (parotid and other glands) are biologically different from squamous cell carcinoma — there are many subtypes, treatment is usually surgery-led (often with radiation), and chemotherapy/immunotherapy roles differ. Sinonasal cancers (nasal cavity and sinuses) are uncommon and varied. If you have one of these, ask your team how your cancer differs from typical “head and neck squamous cell carcinoma,” because much of the squamous-cell information won't apply directly.

How stage maps to treatment intensity

Early stage (I–II): usually one treatment — surgery alone or radiation alone.
Locally advanced (III–IVA/IVB): usually combination treatment — chemoradiation, or surgery followed by radiation or chemoradiation; immunotherapy around surgery may be added in resectable disease.
Recurrent or metastatic (IVC / cancer that returns or spreads): treatment shifts toward immunotherapy and chemotherapy to control the cancer and extend life, sometimes with salvage surgery or re-irradiation for cancer that comes back in one spot.

Caregiver note. Staging conversations are full of letters and numbers. It can help to ask the team to write down, in plain words, three things: (1) the subsite and HPV/EBV status, (2) the overall stage and what it means, and (3) whether the goal is cure. Keep that single page at the front of your binder.

What is my exact stage, and is it based on the HPV-positive staging system or the standard one?
Has the cancer spread to lymph nodes in my neck? To anywhere else?
Given my subsite and stage, is this early-stage (one treatment) or locally advanced (combination treatment)?
What are the realistic chances of cure, and how does my HPV/EBV status change that?
If I have a salivary gland or sinus cancer, how is my treatment different from squamous cell carcinoma?

Early-Stage Treatment (Stage I–II)

For early-stage head and neck cancer, the encouraging news is that a single treatment is often enough to cure it. The two main options — surgery alone or radiation alone — usually offer similar chances of cure for early disease. The choice often comes down to which one best preserves your function (speech, swallowing) and fits your situation.

Surgery or radiation — not both. For most early-stage cancers, you don't need both. The decision balances cure rate, side effects, your overall health, and your preferences. This is a genuine choice worth discussing in depth, ideally with both a surgeon and a radiation oncologist.

Surgery for early disease

Removing the tumor surgically can be definitive for early cancers. The approach depends on subsite:

Oral cavity cancers are usually treated with surgery first.
Selected oropharyngeal (throat) cancers can be removed through the mouth using transoral robotic surgery (TORS) or transoral laser surgery — no external incision, often faster recovery, and sometimes the chance to avoid or reduce radiation.
Early larynx cancers can sometimes be treated with limited (organ-preserving) surgery that keeps the voice.
The surgeon often also samples or removes neck lymph nodes (a neck dissection) to check for spread.

Transoral robotic surgery lets the surgeon reach and remove certain throat tumors through the open mouth, guided by a robotic system, with no external cut. For carefully selected oropharyngeal cancers (often HPV-positive), it can remove the tumor and provide detailed pathology that guides whether any radiation is needed afterward. Not every tumor is suitable — location and size matter — and TORS is most available at experienced centers. Ask whether you are a candidate and what the pathology results might mean for additional treatment.

Radiation for early disease

Modern radiation — especially intensity-modulated radiotherapy (IMRT) — shapes the radiation dose precisely around the tumor while sparing nearby healthy tissue like the salivary glands. For many early cancers (including early larynx cancer), radiation alone offers excellent cure rates and can avoid surgery. Proton therapy is available at some centers and may further reduce dose to healthy tissue in selected cases.

Before any radiation: see the dentist. Even for early-stage radiation, a pre-treatment dental evaluation (with any needed extractions done first) is essential to prevent the serious jaw complication called osteoradionecrosis. This is true at every stage.

Larynx (voice box) preservation

For early larynx cancer, preserving the voice is usually very achievable — with radiation or with limited surgery. The goal is to cure the cancer while keeping you able to speak and breathe normally. Your team should explicitly discuss how each option affects your voice.

Caregiver note. Even “single-modality” treatment has real recovery needs. After throat or mouth surgery, expect temporary changes in eating and speaking; after radiation, side effects often build over several weeks and peak near the end. Plan support for the back half of radiation, not just the start.

For my early-stage cancer, are surgery and radiation truly equivalent options? What do you recommend and why?
If surgery: is TORS or another minimally invasive approach possible? Will you also operate on my neck nodes?
How will each option affect my speech, swallowing, and voice — short-term and long-term?
If I have surgery, how likely is it that I'll still need radiation afterward, and how would that be decided?
If radiation: will it be IMRT? Is proton therapy an option for me, and would it help?
Have I had my dental evaluation and any needed extractions scheduled before radiation?
Am I eligible for any clinical trials, including ones studying gentler treatment for HPV-positive cancer?

Locally Advanced Treatment (Stage III–IVB)

“Locally advanced” means the cancer is larger and/or has spread to neck lymph nodes, but not to distant organs. This stage usually needs combination (multimodality) treatment — and, importantly, it is frequently curable. The two main roads are (1) chemoradiation, or (2) surgery followed by radiation or chemoradiation. Increasingly, immunotherapy is added around surgery.

This is a curable stage for many people. Multimodality treatment is intensive, but it works — often while preserving your voice and swallowing. The intensity is the price of cure, and supportive care (next section) makes it manageable.

Road 1: Definitive chemoradiation

For many locally advanced cancers — especially of the throat, larynx, and hypopharynx — the standard is radiation given together with the chemotherapy cisplatin (“concurrent chemoradiation”). Adding cisplatin to radiation meaningfully raises cure rates compared with radiation alone. The classic schedule is high-dose cisplatin every 3 weeks during radiation; some patients receive lower-dose weekly cisplatin instead, depending on fitness and tolerance.

Cetuximab is a fallback, not an equal. When cisplatin can't be given (for example, due to kidney problems, hearing loss, or frailty), radiation may be combined with cetuximab instead. But large trials (RTOG 1016 and De-ESCALaTE) showed that, for HPV-positive throat cancer, cetuximab-radiation produced worse cancer control than cisplatin-radiation. So cetuximab-radiation is reserved for people who genuinely cannot take cisplatin — it is not a gentler “equivalent.”

Road 2: Surgery with risk-adapted radiation afterward

For some cancers (especially oral cavity, and selected throat cancers via TORS), surgery comes first. What's found at surgery then guides whether you need additional treatment:

Favorable findings: surgery alone, or surgery plus radiation, may be enough.
“Adverse features”: if the surgeon finds cancer at the edge of what was removed (positive margins) or cancer that has broken out of a lymph node (extranodal extension), then chemoradiation after surgery (chemo added to radiation) lowers the chance of recurrence. Other features (multiple involved nodes, nerve or vessel invasion) may call for radiation after surgery.

The big recent change: immunotherapy around surgery (KEYNOTE-689)

A practice-changing advance. In June 2025, the FDA approved pembrolizumab (an immunotherapy) given around surgery for resectable locally advanced head and neck squamous cell carcinoma whose tumor expresses PD-L1 (a CPS score of 1 or higher). In the KEYNOTE-689 trial, the regimen — pembrolizumab before surgery, then pembrolizumab plus radiation (with or without cisplatin) after surgery, then pembrolizumab on its own for a while — significantly delayed cancer recurrence compared with standard treatment (median event-free survival about 51.8 months vs 30.4 months). This is the first time immunotherapy has shown this kind of benefit in earlier-stage, potentially curable head and neck cancer. Ask whether you are a candidate.

Locally advanced nasopharyngeal cancer

Nasopharyngeal cancer follows its own path. Locally advanced disease is typically treated with chemoradiation, often after induction chemotherapy (commonly gemcitabine plus cisplatin given first to shrink the cancer). Increasingly, immunotherapy is being integrated. Your team may use a blood EBV DNA level to help gauge risk and follow your response.

Because HPV-positive throat cancer is so curable, many patients understandably ask: “Can I have less treatment and fewer long-term side effects?” Researchers are actively testing this — lower radiation doses, less chemotherapy, and surgery-based approaches. But a major US trial, NRG-HN005, was stopped early after the standard treatment performed extremely well (about 98% of patients free of cancer progression at 2 years) and the gentler arms did not match it. The clear message: de-escalation is promising but still experimental, and should only be done inside a clinical trial. Outside a trial, getting full-strength standard treatment gives you the best proven chance of cure.

Caregiver note. Locally advanced treatment is the most demanding phase. Chemoradiation typically runs 6–7 weeks, with side effects (severe mouth sores, dry mouth, painful swallowing, weight loss, fatigue) building toward the end and lasting weeks beyond it. Expect many appointments across surgery, radiation, medical oncology, dentistry, speech therapy, and nutrition. Practical help with rides, meals/feeding, mouth care, and medication schedules makes an enormous difference. See the Side Effects and Survivorship sections for specifics.

Is my best path definitive chemoradiation, or surgery followed by radiation/chemoradiation? Why?
Will I get cisplatin? High-dose every 3 weeks, or weekly? How will you protect my kidneys and hearing?
If I can't take cisplatin, what are my options — and what are the trade-offs of cetuximab?
Am I a candidate for perioperative pembrolizumab (KEYNOTE-689)? Has my tumor's PD-L1 (CPS) been tested?
If I have surgery first, what adverse features would mean I need chemoradiation afterward?
For nasopharyngeal cancer: will I have induction chemotherapy? Will immunotherapy be added? Will you monitor EBV DNA?
What is your plan to preserve my voice and swallowing? Will I see speech therapy before treatment starts?
Is a feeding tube likely, and would it be placed ahead of time or only if needed?
Are there clinical trials I should consider, including de-escalation trials for HPV-positive cancer?

Recurrent, Metastatic & Immunotherapy

If head and neck cancer comes back after treatment (recurrent) or has spread to distant parts of the body (metastatic), the goal usually shifts from cure to controlling the cancer, extending life, and maintaining quality of life — though cure is sometimes still possible for cancer that returns in a single, treatable spot. This is the area where immunotherapy has made the biggest difference.

Immunotherapy has changed the outlook. Checkpoint inhibitors — drugs that release the brakes on the immune system — now help many people with recurrent or metastatic head and neck cancer live longer than they would on older chemotherapy, sometimes with durable responses. They have become the foundation of first-line treatment.

First-line treatment: the role of your PD-L1 (CPS) score

For most recurrent/metastatic squamous cell head and neck cancer, the first-line standard is based on the KEYNOTE-048 trial and depends on a tumor score called the PD-L1 combined positive score (CPS), which estimates how much the immune-checkpoint target is present:

Higher CPS: pembrolizumab alone is often preferred — immunotherapy without chemotherapy.
Lower CPS, or when faster tumor shrinkage is needed: pembrolizumab plus chemotherapy (a platinum drug plus fluorouracil) is used.

Both approaches improved survival compared with the older “EXTREME” cetuximab-chemotherapy regimen. Your CPS score is therefore an important number to ask about.

If cancer progresses after platinum chemotherapy

For cancer that worsens during or shortly after platinum-based chemotherapy, nivolumab (another checkpoint inhibitor) improved survival compared with standard chemotherapy in the CheckMate-141 trial, with responses that can last. Cetuximab-based combinations remain an option in some situations.

Recurrent/metastatic nasopharyngeal cancer

For recurrent or metastatic nasopharyngeal cancer, immunotherapy plus chemotherapy is now standard. In the US, toripalimab (with gemcitabine and cisplatin) is FDA-approved as first-line treatment, and as a single agent after platinum chemotherapy, based on the JUPITER-02 trial — the first PD-1 immunotherapy approved in the US for this disease. A second US option, penpulimab-kcqx, was FDA-approved in April 2025 — with platinum chemotherapy and gemcitabine for first-line recurrent or metastatic non-keratinizing nasopharyngeal cancer, and as a single agent after platinum chemotherapy plus at least one other treatment. (Other PD-1 drugs such as camrelizumab and tislelizumab are used in other regions.) Blood EBV DNA can help monitor the cancer.

Cancer that returns in one spot

When head and neck cancer comes back in a single, localized area (and hasn't spread widely), treatment with curative intent may still be possible — through salvage surgery or, in selected cases, re-irradiation. These decisions are complex and weigh the chance of cure against added side effects; they belong at an experienced multidisciplinary center.

Immunotherapy side effects are different from chemo. Checkpoint inhibitors can cause the immune system to attack normal organs — the skin, gut (diarrhea/colitis), thyroid and other glands, liver, or lungs. Most issues are manageable when caught early, but they can become serious. Report new or worsening symptoms promptly (rashes, persistent diarrhea, fatigue, shortness of breath, new aches) rather than waiting.

Caregiver note. In advanced disease, watch for the immune-related side effects above and help track symptoms between visits. Also watch for emergencies: difficulty breathing, heavy bleeding from the mouth or throat, or sudden inability to swallow saliva — these need urgent care. Emotional support matters as much as logistics; this phase carries a lot of uncertainty, and you don't have to navigate it alone (see resources under Survivorship).

Is my cancer recurrent, metastatic, or both? Is cure still possible, or is the goal control?
What is my tumor's PD-L1 (CPS) score, and how does it guide first-line treatment?
Should I have pembrolizumab alone or pembrolizumab plus chemotherapy?
If my cancer progressed after platinum chemo, is nivolumab right for me?
For nasopharyngeal cancer: is toripalimab plus chemotherapy an option? Will you monitor EBV DNA?
If my cancer came back in one spot, could salvage surgery or re-irradiation cure it?
What immune-related side effects should I watch for, and who do I call?
Are there clinical trials of new immunotherapy combinations or other approaches for me?
Would palliative care involvement help with symptoms and decision-making? (It can be added alongside active treatment.)

Side Effects & Supportive Care

Head and neck cancer treatment can be hard on the very functions you use every day — eating, talking, breathing. The good news is that most side effects are expected, preventable, or treatable, and a strong supportive-care team makes treatment far more manageable. These services are part of your treatment, not extras.

Protect your jaw: dental care before radiation. Radiation reduces the jaw's ability to heal, so a tooth problem or extraction after radiation can trigger osteoradionecrosis — a painful, hard-to-heal breakdown of the jawbone. Prevention is far easier than treatment: have a full dental evaluation and any needed extractions before radiation, then keep up meticulous dental care (including daily fluoride trays) for life.

During treatment (especially chemoradiation)

Mouth and throat sores (mucositis). Painful inflammation of the lining of the mouth and throat, usually peaking in the later weeks of radiation. Managed with good mouth care, salt/baking-soda rinses, prescription mouthwashes, and pain medication (sometimes including opioids). Tell your team early — pain control protects your ability to eat and drink.
Dry mouth (xerostomia). Radiation can damage salivary glands. Modern IMRT spares the glands much better than older radiation, and proton therapy may help further in some cases. Saliva substitutes, frequent sips of water, and prescription medicines can ease it; some dryness may persist long-term.
Difficulty and pain swallowing (dysphagia). Swelling and soreness make swallowing hard. A speech-language pathologist teaches swallowing exercises — ideally started before and during treatment to keep the muscles working, which improves long-term swallowing.
Weight loss and nutrition. Eating becomes a daily challenge. A dietitian helps maintain calories and protein; high-calorie liquids and soft foods help. Maintaining nutrition is critical to completing treatment.
Taste changes, thick mucus, skin reactions, and fatigue are common and usually improve after treatment ends.
Cisplatin side effects: can include kidney strain, hearing loss/ringing (ototoxicity), nausea, and low blood counts — monitored closely, with the schedule (every-3-weeks vs weekly) chosen partly to balance these.

Some people need a temporary feeding tube to maintain nutrition and hydration when swallowing becomes too painful. Teams differ on whether to place one ahead of time (prophylactic) or only if needed (reactive). A key principle: even with a feeding tube, it's important to keep swallowing small amounts (as your team allows) and doing swallowing exercises, so the muscles don't weaken from disuse. Most tubes are temporary and removed once you can eat enough by mouth. Ask your team about their approach and the plan for getting back to eating.

Longer-term effects to watch for

Persistent dry mouth and dental risk — lifelong fluoride and dental vigilance.
Swallowing problems and aspiration — ongoing speech-therapy support; watch for coughing/choking with eating or signs of aspiration pneumonia (fever, productive cough, shortness of breath).
Jaw stiffness (trismus) — stretching exercises and devices can help; start early.
Neck/face swelling (lymphedema) — specialized lymphedema therapy helps.
Underactive thyroid (hypothyroidism) after neck radiation — checked with periodic blood tests and easily treated.
Carotid artery and other late effects — discussed and monitored as part of survivorship.
Voice changes — speech therapy and, after laryngectomy, voice rehabilitation options.

Call your team or seek emergency care for: trouble breathing or noisy breathing; heavy bleeding from the mouth or throat; inability to swallow your own saliva; high fever (possible infection while blood counts are low); signs of aspiration pneumonia; signs of dehydration (dizziness, very dark/low urine, confusion); or uncontrolled pain. These need prompt attention.

Caregiver note — this is where you make the biggest difference. Practical jobs that matter: help with a strict mouth-care routine (gentle rinses, moisturizing, avoiding irritants like alcohol-based mouthwash, tobacco, and spicy/acidic foods); keep a medication and pain schedule so pain stays ahead of, not behind, the sores; support nutrition and hydration (and feeding-tube care if needed) and track weight; drive to and sit in on the many appointments; cue the daily swallowing and jaw exercises; and offer steady emotional support through changes in appearance, voice, and eating. Supporting tobacco and alcohol cessation is one of the most valuable things you can do — it improves how well treatment works and lowers the risk of new cancers.

What side effects should I expect during treatment, and when will they peak?
What is the plan to control mouth/throat pain so I can keep eating and drinking?
Will my radiation be IMRT (or proton therapy) to reduce dry mouth?
Will I see a speech-language pathologist to start swallowing exercises before treatment?
What's your approach to feeding tubes — placed ahead of time or only if needed?
How will you monitor my kidneys, hearing, and blood counts on cisplatin?
What long-term effects should I watch for, and what's the plan to prevent jaw problems (osteoradionecrosis)?
Who do I call after hours, and what counts as an emergency?

Survivorship, Prevention & Resources

Finishing treatment is a milestone — and the beginning of a new phase. Survivorship focuses on watching for recurrence and second cancers, recovering function (swallowing, voice, dental health), managing long-term effects, and living well. Many people regain meaningful quality of life.

Follow-up and surveillance

Regular check-ups with your team (more frequent in the first 2 years, when most recurrences occur, then spacing out) including exams of the mouth, throat, and neck.
Imaging as indicated — often a PET-CT a few months after treatment to confirm response, then scans based on symptoms and exam.
EBV DNA blood tests for nasopharyngeal cancer to watch for recurrence.
Watch for second primary cancers. People with tobacco/alcohol-related head and neck cancer have a higher risk of new cancers elsewhere in the mouth, throat, esophagus, and lungs — another reason cessation matters.
Lifelong dental care and thyroid checks after neck radiation.
Report new symptoms promptly — a new lump, new pain, persistent hoarseness, or trouble swallowing.

Prevention — for you and your family

HPV vaccination prevents many of these cancers. The HPV vaccine protects against the HPV types that cause most HPV-related throat cancers (as well as cervical and other cancers). Many countries now vaccinate both girls and boys. If you have children or grandchildren in the recommended age range, vaccination is one of the most powerful prevention steps available. Tobacco and alcohol cessation dramatically lowers risk for the smoking/drinking-related cancers and improves outcomes if cancer occurs.

Clinical Trials

Clinical trials offer access to tomorrow's treatments today, and they drive the progress that has improved outcomes. Asking about trials is worthwhile at any stage and in any region.

How to search: ClinicalTrials.gov is the main US/international registry — search by your condition and location. The WHO ICTRP portal (trialsearch.who.int) covers global trials. Ask your cancer center's research office and your oncologist directly.
De-escalation trials (HPV-positive throat cancer): trials such as NRG-HN005 (NCT03952585) have tested gentler treatment; though that specific trial closed early in favor of standard treatment, the field is active — ask what is currently enrolling.
Immunotherapy trials: the regimens behind today's standards came from trials like KEYNOTE-689 (NCT03765918, perioperative pembrolizumab), KEYNOTE-048 (NCT02358031, first-line R/M), and CheckMate-141 (NCT02105636, platinum-refractory). New combinations are constantly being tested.
Nasopharyngeal cancer trials: e.g., the immunotherapy work behind JUPITER-02 (NCT03581786, toripalimab).

Trial availability changes constantly; confirm current status on ClinicalTrials.gov or with your team.

Failed & De-adopted Therapies (Be Skeptical)

You'll encounter many claims online. Here are approaches that have not held up in rigorous testing, so you can recognize them:

Cetuximab as an “equal” swap for cisplatin in HPV-positive cancer. Tested directly (RTOG 1016, De-ESCALaTE) and found inferior for cancer control. It's a fallback for people who can't take cisplatin, not an equivalent.
De-escalation off-trial. Reducing radiation/chemo outside a clinical trial is not supported — NRG-HN005 showed standard treatment still won. Don't accept “less” treatment outside a trial just to reduce side effects.
Adding certain immunotherapies to chemoradiation in locally advanced disease. Some trials adding checkpoint inhibitors to standard chemoradiation (for example, avelumab in the JAVELIN Head & Neck 100 trial) did not improve outcomes. (Perioperative pembrolizumab in KEYNOTE-689 is a different, positive story.)
High-dose antioxidant supplements during radiation. A randomized trial found that high-dose vitamin E (alpha-tocopherol) during radiation was associated with worse cancer outcomes. Avoid high-dose antioxidant/herbal supplements during radiation unless your oncologist approves — some can interfere with treatment.
“Alternative” cures in place of standard treatment. Replacing surgery/radiation/chemo with unproven alternatives costs precious time during a curable window. Complementary approaches for symptom relief can be fine — but discuss everything with your team, especially supplements (which can interact with chemo and immunotherapy).

Specialty Center Directory

Head and neck cancer outcomes are better at high-volume, multidisciplinary centers. Always verify current phone numbers and services, which can change.

Huntsman Cancer Institute, University of Utah (Salt Lake City) — the region's NCI-designated comprehensive cancer center, with a multidisciplinary head and neck program: head and neck surgery, transoral robotic surgery, medical and radiation oncology (including proton therapy), dental oncology, speech-language pathology, nutrition, and clinical trials. Cancer Hospital main line: 1-877-585-0303 / 801-587-7000.
University of Utah Health — Otolaryngology / Head & Neck Surgery (Salt Lake City) — surgical evaluation, microvascular reconstruction, and coordination with radiation and medical oncology. Main: 801-581-2121.
Intermountain Health cancer centers (Wasatch Front & Intermountain West) — medical and radiation oncology, head and neck surgery, and supportive services. Find a location via Intermountain Health.
George E. Wahlen VA Medical Center (Salt Lake City) — head and neck cancer care for veterans. Main: 801-582-1565.

NCI-designated comprehensive cancer centers with major head and neck programs include (verify current contacts):

MD Anderson Cancer Center (Houston) — 1-877-632-6789
Memorial Sloan Kettering Cancer Center (New York) — 1-800-525-2225
Dana-Farber / Brigham (Dana-Farber Brigham Cancer Center) (Boston) — 1-877-442-3324
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (Baltimore) — 410-955-5222
University of Pittsburgh (UPMC Hillman), University of Michigan Rogel, Vanderbilt-Ingram, Mayo Clinic, and others with strong head and neck and TORS programs.

To find one near you: NCI's center directory (cancer.gov/research/infrastructure/cancer-centers/find).

Veterans — who carry a high burden of tobacco-related head and neck cancer — can receive care through the VA, including at the George E. Wahlen VA Medical Center in Salt Lake City. Ask about service-connection for tobacco-related and certain exposure-related cancers, which can affect benefits. The VA also coordinates with academic centers (including the University of Utah) for specialized surgery and radiation. VA general line: 1-877-222-8387.

Care is delivered through provincial cancer agencies and academic centers, with drug coverage governed provincially (national assessment via CADTH; Quebec via INESSS). Major head and neck programs include Princess Margaret Cancer Centre (Toronto), BC Cancer (Vancouver), and centers in Montreal, Calgary, and elsewhere. Coverage and access to newer immunotherapies can vary by province — ask the center's pharmacy/financial navigator about your specific drugs.

UK: The Royal Marsden (London); care guided by NICE.
Europe: Gustave Roussy (France); large ESMO-affiliated academic centers across Germany, Italy, and Spain.
Nasopharyngeal cancer (endemic regions): Sun Yat-sen University Cancer Center (Guangzhou, China) is a leading center for NPC research and care; major centers in Hong Kong, Taiwan, and Singapore.
South Asia (high oral-cancer burden): Tata Memorial Centre (Mumbai, India).
Australia: Peter MacCallum Cancer Centre (Melbourne); protocols via eviQ.

International Access & Regulatory Landscape

Core treatments (surgery, radiation, chemoradiation, immunotherapy) are recommended by major guidelines worldwide (NCCN in the US, ESMO in Europe, and others), but access and timing of approvals differ:

Pembrolizumab and nivolumab for recurrent/metastatic disease are widely approved (US FDA, EMA in Europe, PMDA in Japan, Health Canada, NICE in the UK, NMPA in China).
Perioperative pembrolizumab (KEYNOTE-689) was FDA-approved in June 2025; approval and adoption in other regions (EMA, etc.) follow on their own timelines — ask whether it's available where you are.
Nasopharyngeal-cancer immunotherapies reach regions at different times: toripalimab (FDA-approved 2023), camrelizumab, and tislelizumab were approved earlier in China; availability elsewhere varies.
Advanced modalities — proton therapy, robotic surgery (TORS), and microvascular reconstruction — are unevenly available worldwide, which shapes organ-preservation options.
Prevention and disease patterns differ: HPV-related throat cancer is rising in North America, Northern/Western Europe, and Australia; betel/areca-nut and smokeless-tobacco oral cancers are common in South/Southeast Asia; EBV-related nasopharyngeal cancer is endemic in southern China and Southeast Asia.

Glossary

Squamous cell carcinoma (SCC): the most common type of head and neck cancer, starting in the flat lining cells of the mouth/throat.
Subsite: the specific location where the cancer starts (e.g., oropharynx, larynx).
Oropharynx: the middle throat — tonsils, base of tongue, soft palate.
Nasopharynx: the upper throat behind the nose.
HPV / p16: human papillomavirus; p16 is a protein marker used to identify HPV-driven (better-prognosis) throat cancer.
EBV: Epstein-Barr virus, linked to nasopharyngeal cancer; tracked with a blood EBV DNA test.
AJCC 8th edition: the staging system (TNM) used to describe how advanced a cancer is.
TNM: Tumor size/extent, lymph Nodes, and Metastasis — combined into a stage.
IMRT: intensity-modulated radiotherapy — precise radiation that spares healthy tissue.
Proton therapy: a radiation type that can further limit dose to nearby healthy tissue in selected cases.
TORS: transoral robotic surgery — removing throat tumors through the mouth with no external incision.
Chemoradiation: chemotherapy (usually cisplatin) given together with radiation.
Cisplatin: the main chemotherapy paired with radiation for locally advanced disease.
Cetuximab: an EGFR-targeted antibody; a fallback when cisplatin can't be used.
Checkpoint inhibitor / immunotherapy: drugs (pembrolizumab, nivolumab, toripalimab) that release the brakes on the immune system.
PD-L1 / CPS: a tumor marker and its “combined positive score,” used to guide immunotherapy choices.
Extranodal extension (ENE): cancer that has broken out of a lymph node — an “adverse feature” that may mean chemoradiation after surgery.
Positive margin: cancer found at the edge of removed tissue — another adverse feature.
Mucositis: painful inflammation of the mouth/throat lining during treatment.
Xerostomia: dry mouth.
Dysphagia: difficulty swallowing.
Osteoradionecrosis (ORN): breakdown of jawbone after radiation — prevented with dental care before radiation.
Trismus: jaw stiffness/limited opening.
Laryngectomy: surgical removal of the voice box (avoided when organ preservation is possible).
De-escalation: gentler (reduced) treatment being studied for HPV-positive cancer — still experimental.
Adjuvant / neoadjuvant: treatment given after / before the main treatment (e.g., surgery).

Key References & Sources

Guidelines:

NCCN Clinical Practice Guidelines in Oncology — Head and Neck Cancers (current version).
ESMO Clinical Practice Guidelines — Squamous Cell Carcinoma of the Head and Neck; and Nasopharyngeal Carcinoma.
ASCO and ASTRO guidelines on chemoradiation and adjuvant therapy; ASCO/CAP HPV testing guidance.
NICE (UK) head and neck cancer guidance.

Landmark trials referenced:

KEYNOTE-689 (NCT03765918) — perioperative pembrolizumab, resectable locally advanced HNSCC (FDA approval June 2025).
KEYNOTE-048 (NCT02358031) — first-line pembrolizumab (CPS-guided), recurrent/metastatic HNSCC.
CheckMate-141 (NCT02105636) — nivolumab, platinum-refractory recurrent/metastatic HNSCC.
RTOG 1016 (NCT01302834) and De-ESCALaTE HPV — cetuximab inferior to cisplatin with radiation in HPV-positive disease.
RTOG 9501 / EORTC 22931 — adjuvant chemoradiation for adverse features (positive margins, extranodal extension).
RTOG 91-11 — larynx preservation with concurrent chemoradiation.
JUPITER-02 (NCT03581786) — toripalimab plus chemotherapy in recurrent/metastatic nasopharyngeal carcinoma.
NRG-HN005 (NCT03952585) — de-escalation in HPV-positive oropharyngeal cancer (standard treatment remained superior).

Patient organizations & resources:

Head and Neck Cancer Alliance (headandneck.org) — education and support.
Support for People with Oral and Head and Neck Cancer (SPOHNC) (spohnc.org) — survivor support.
National Cancer Institute (cancer.gov) and American Cancer Society (cancer.org).
Tobacco/alcohol cessation: Utah Tobacco Quit Line and the national line 1-800-QUIT-NOW (1-800-784-8669).
Clinical trials: ClinicalTrials.gov and WHO ICTRP (trialsearch.who.int).

For Caregivers: A Dedicated Toolkit

You are part of the care team. Head and neck cancer asks a lot of caregivers because it touches eating, speaking, and breathing. Here's a practical checklist:

Side-effect management: support a strict mouth-care routine; keep pain medication on schedule (ahead of the sores); help manage dry mouth, thick mucus, and skin care.
Nutrition & feeding tube: track weight, encourage high-calorie/high-protein intake, learn feeding-tube care if needed, and keep some swallowing going (as allowed) to protect the muscles.
Appointments: expect many, across surgery, radiation, medical oncology, dentistry, speech therapy, and nutrition; keep a shared calendar and drive/attend when you can.
Cessation support: help with quitting tobacco and alcohol — it improves treatment results and lowers second-cancer risk (1-800-QUIT-NOW).
Rehabilitation: cue and join the daily swallowing and jaw-stretching exercises.
Watch for emergencies: trouble breathing, heavy bleeding from the mouth/throat, inability to swallow saliva, signs of aspiration pneumonia (fever, cough, breathlessness) — seek urgent care.
Emotional support: changes in appearance, voice, and eating are hard; listen, normalize, and connect to support groups (SPOHNC, Head and Neck Cancer Alliance).
Care for yourself: caregiver burnout is real. Accept help, take breaks, and use the cancer center's social work and support services — they're for you too.

What is my follow-up schedule, and what scans or blood tests (e.g., EBV DNA) will I have?
What long-term side effects should I watch for, and who manages them?
How do we monitor for recurrence and for a second cancer?
Do I need ongoing dental care, thyroid checks, or swallowing therapy?
What support is available for my voice, swallowing, dry mouth, and emotional health?
Should my family consider HPV vaccination?
What help is available to quit tobacco and alcohol, for me and my caregiver's peace of mind?
Are there survivorship programs or support groups you recommend?

Fertility, Pregnancy & Head and Neck Cancer

HPV-associated head and neck cancers increasingly affect younger adults in their 30s and 40s. If you are of reproductive age, fertility and pregnancy planning deserve early attention.

Fertility preservation before treatment

Before chemotherapy or radiation — cisplatin and other platinum-based drugs damage eggs and sperm. Radiation to the neck and head can affect the pituitary gland and thyroid (both of which are important for reproduction). Discuss fertility preservation before treatment begins: egg or embryo freezing (women), sperm banking (men).
Radiation and gonads — for most head and neck cancers, the radiation field is not near the ovaries, so ovarian function is usually not directly affected. However, scatter radiation and pituitary involvement are possible; discuss with your radiation oncologist.

Pregnancy after head and neck cancer treatment

Timing — most oncologists recommend waiting 2 years after completing treatment (the period of highest recurrence risk) before attempting pregnancy. Discuss your specific situation with your team.
Thyroid monitoring — radiation to the neck commonly causes hypothyroidism over months to years. Thyroid hormone levels (TSH, free T4) should be checked and normalized before and throughout pregnancy, as untreated hypothyroidism is harmful to a developing baby.
Nutritional status — treatment-related dysphagia, dry mouth (xerostomia), and weight changes must be addressed before pregnancy. Work with a dietitian to ensure adequate nutrition (especially folate, iron, and protein) throughout pregnancy.
Checkpoint inhibitors (pembrolizumab, nivolumab) — these immunotherapy drugs must not be used during pregnancy. Effective contraception is required during treatment. If you are taking a checkpoint inhibitor and become pregnant, contact your oncologist immediately.

HPV vaccination and your family

If your cancer was HPV-associated, your partner and children of eligible age (up to 26 years; up to 45 years with shared decision-making) should be offered HPV vaccination to reduce their own future risk. Discuss with your primary care provider or oncologist.

Before pregnancy after HNC treatment: confirm thyroid function is normal, ensure complete nutritional recovery, and verify that all treatment is complete and you are in remission. Work with a maternal-fetal medicine specialist if you have ongoing treatment-related complications.

Important disclaimer. This guide is for education and is not medical advice. Head and neck cancer care is highly individualized and the evidence evolves quickly. Treatment decisions must be made with your own multidisciplinary team, who know your specific situation. Drug approvals, trial availability, and contact details change — always verify current information with your care team and official sources.